Evidence map›Paper›PMID 37391684›Full record

ArticleJournal of natural medicines2023

Fucoxanthin exert dose-dependent antifibrotic and anti-inflammatory effects on CCl

Vasilii N Slautin, Dmitry Yu Grebnev, Irina Yu Maklakova, Sergey V Sazonov

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vasilii N SlautinFederal State Budgetary Institution of Higher Professional Education, Ural State Medical University", 3, Repin Street, 620028, Yekaterinburg, Russian Federation. slautinvasilij@gmail.com.ORCID http://orcid.org/0000-0003-3967-0442
Dmitry Yu GrebnevFederal State Budgetary Institution of Higher Professional Education, Ural State Medical University", 3, Repin Street, 620028, Yekaterinburg, Russian Federation.ORCID http://orcid.org/0000-0002-5698-8404
Irina Yu MaklakovaFederal State Budgetary Institution of Higher Professional Education, Ural State Medical University", 3, Repin Street, 620028, Yekaterinburg, Russian Federation.ORCID http://orcid.org/0000-0002-6895-7947
Sergey V SazonovFederal State Budgetary Institution of Higher Professional Education, Ural State Medical University", 3, Repin Street, 620028, Yekaterinburg, Russian Federation.ORCID http://orcid.org/0000-0001-7064-0079
Ural State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lack of an effective non-surgical liver fibrosis treatment is a major problem in hepatology. Fucoxanthin is a marine xanthophyll that exhibits anti-inflammatory, antioxidant, and hepatoprotective properties, thereby indicating its potential effectiveness in the treatment of liver fibrosis. The study aims to investigate the antifibrotic and anti-inflammatory effects of fucoxanthin and its main mechanisms on carbon tetrachloride (CCl

Indexed as

Liver CirrhosisTumor Necrosis Factor-alphaAnimalsAnti-Inflammatory AgentsLiverMiceMice, Inbred ICRXanthophyllsAnti-Inflammatory AgentsfucoxanthinTumor Necrosis Factor-alphaXanthophyllsFucoxanthinInflammationLiver fibrosisMMP-9MyofibroblastsTGF-β

Identifiers

PMID37391684
OpenAlexW4382677568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.